SEC Form 4
Perspective Therapeutics, Inc. (CATX) insider trading
In the 12 months to Oct 26, 2026, 2 CATX insiders reported open-market sales of $1.6M across 6 filings; 2 insiders bought $42.2K.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $1.6M
- 6 filings · 2 insiders
- Open-market purchases
- $42.2K
- 2 filings
Who traded CATX, and when
- Purchase
- Sale
CATX daily close from Oct 27, 2025 to Oct 26, 2026, between $1.20 and $5.65, last $1.20. 6 sale and 2 purchase filings by 4 insiders, marked at their filing dates. Lantheus Alpha Therapy, LLC, 10% owner: sold $883.2K across 2 filings, first filed Sep 4, 2026, last Sep 8, 2026. Lantheus Holdings, Inc., 10% owner: sold $739.3K across 4 filings, first filed Sep 2, 2026, last Sep 8, 2026. Jonathan Robert Hunt, Chief Accounting Officer: bought $22.3K across 1 filing, first filed Nov 17, 2025, last Nov 17, 2025. Robert F. Williamson III, Director: bought $19.9K across 1 filing, first filed Nov 14, 2025, last Nov 14, 2025.
Largest mark · tap a row for others
Lantheus Alpha Therapy, LLC · 10% owner
Filing 1 of 2 within a week · $883,235 total
Sale $357,184
113,914 shares at $3.14 avg
Filed Sep 4, 2026 · traded Aug 31
Close on filing date $3.13
Lantheus Alpha Therapy, LLC · 10% owner
10% owner
$883.2K soldLantheus Holdings, Inc. · 10% owner
10% owner
$739.3K soldJonathan Robert Hunt · Chief Accounting Officer
Chief Accounting Officer
$22.3K boughtRobert F. Williamson III · Director
Director
$19.9K boughtOpen-market trades
8 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Lantheus Alpha Therapy, LLC | 10% owner | $883.2K | — | 2 | — | |
| Lantheus Holdings, Inc. | 10% owner | $739.3K | — | 4 | — | |
| Jonathan Robert Hunt | Chief Accounting Officer | — | $22.3K | 1 | — | |
| Robert F. Williamson III | Director | — | $19.9K | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Lantheus Alpha Therapy, LLC 10% owner | Sale | 167,149 | $3.15 | $526.1K | 11,273,364 | |
traded | Lantheus Holdings, Inc. 10% owner | Sale | 80,783 | $3.11 | $250.9K | 11,440,513 | |
traded | Lantheus Alpha Therapy, LLC 10% owner | Sale | 113,914 | $3.14 | $357.2K | 11,563,425 | |
traded | Lantheus Holdings, Inc. 10% owner | Sale | 42,129 | $3.11 | $131.2K | 11,521,296 | |
traded | Lantheus Holdings, Inc. 10% owner | Sale | 35,769 | $3.12 | $111.6K | 11,563,425 | |
traded | Lantheus Holdings, Inc. 10% owner | Sale | 78,145 | $3.14 | $245.6K | 11,599,194 | |
traded | Jonathan Robert Hunt Chief Accounting Officer | Purchase | 11,000 | $2.03 | $22.3K | 59,800 | |
traded | Robert F. Williamson III Director | Purchase | 9,498 | $2.10 | $19.9K | 9,864 |
GET /stocks/filings/vX/form-4?tickers=CATX&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"CATX"
],
"issuer_cik": "0000728387",
"owner_cik": "0002010224",
"accession_number": "0002064832-26-000318",
"form_type": "4",
"filing_date": "2026-09-08",
"period_of_report": "2026-09-03",
"issuer_name": "Perspective Therapeutics, Inc.",
"issuer_trading_symbol": "CATX",
"owner_name": "Lantheus Alpha Therapy, LLC",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-04",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 167149,
"transaction_price_per_share": 3.1472,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 11273364,
"transaction_value": 526051.3328000001,
"not_subject_to_section_16": true,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F3",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.0448 to $3.1775, inclusive. The reporting person undertakes to provide to CATX, any security holder of CATX or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4."
},
{
"id": "F2",
"description": "Represents securities directly held by Lantheus Alpha Therapy, LLC (\"Lantheus\"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. (\"Lantheus Holdings\"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership."
}
]
},
{
"tickers": [
"CATX"
],
"issuer_cik": "0000728387",
"owner_cik": "0001521036",
"accession_number": "0002064832-26-000318",
"form_type": "4",
"filing_date": "2026-09-08",
"period_of_report": "2026-09-03",
"issuer_name": "Perspective Therapeutics, Inc.",
"issuer_trading_symbol": "CATX",
"owner_name": "Lantheus Holdings, Inc.",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-03",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 80783,
"transaction_price_per_share": 3.1058,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 11440513,
"transaction_value": 250895.8414,
"not_subject_to_section_16": true,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.05 to $3.13, inclusive. The reporting person undertakes to provide to Perspective Therapeutics, Inc. (\"CATX\"), any security holder of CATX or the staff of the Securities and Exchange Commission (\"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4."
},
{
"id": "F2",
"description": "Represents securities directly held by Lantheus Alpha Therapy, LLC (\"Lantheus\"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. (\"Lantheus Holdings\"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has Perspective Therapeutics, Inc.'s CEO sold stock?
No. Johan M. Spoor (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is CATX’s insider data?
These are CATX Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track CATX insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for CATX every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.